Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Japan’s Largest Generic Drug Maker to Expand into Thailand, Malaysia and Hong Kong

By Pharmaceutical Processing | July 28, 2010

Nichi-Iko Pharmaceutical Co., Japan’s biggest generic drug maker, will break into the markets in Thailand, Malaysia and Hong Kong in the next business year as its first overseas business expansion, its president and chief executive officer said Wednesday.

“We find it necessary to compete worldwide” as competition is growing tougher in the domestic market, Yuichi Tamura said at a press conference in Bangkok.

Generic drugs, which contain the same active ingredients of the original formulation, are produced and distributed after the patent protection of the original drugs expires. Demand for the inexpensive drugs is expected to increase in Southeast Asia against the backdrop of the region’s rapid economic growth, according to Nichi-Iko.

Nichi-Iko will sell seven to 13 generic drugs, including a cholesterol-lowering agent, in the three markets as soon as authorization is given by local authorities through sales routes established by DKSH Group of Switzerland, a leading market expansion service provider with focus on Asia, it said.

The company, based in Toyama Prefecture, will target affluent consumers in the three economies where generic drug sales are estimated to total the equivalent of 150 billion yen.

It hopes to capture a 1 percent share of the three markets combined within five years’ time as part of its plan to join the world’s top 10 generic drug makers during the period by doubling its sales to 130 billion yen, it said.

Nichi-Iko is now studying a market advance into Beijing, Shanghai and other Chinese cities, as well as Singapore and the United States, Tamura said.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE